Northern Trust’s Ovid Therapeutics OVID Stock Holding History

Northern Trust’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$566K	Buy	254,804 +88,173	+53%	+$158K	﹤0.01%	3569
2025 Q4	$272K	Buy	166,631 +14,920	+10%	+$23K	﹤0.01%	3871
2025 Q3	$197K	Buy	151,711 +52,593	+53%	+$45.6K	﹤0.01%	3989
2025 Q2	$32.7K	Sell	99,118 -324,500	-77%	-$97.8K	﹤0.01%	4297
2025 Q1	$132K	Sell	423,618 -64,553	-13%	-$39.7K	﹤0.01%	4048
2024 Q4	$456K	Buy	488,171 +7,946	+2%	+$8.89K	﹤0.01%	3690
2024 Q3	$567K	Buy	480,225 +14,693	+3%	+$15.4K	﹤0.01%	3547
2024 Q2	$358K	Sell	465,532 -15,335	-3%	-$42.7K	﹤0.01%	3629
2024 Q1	$1.47M	Sell	480,867 -9,805	-2%	-$32.8K	﹤0.01%	3129
2023 Q4	$1.58M	Buy	490,672 +11,862	+2%	+$40.5K	﹤0.01%	3118
2023 Q3	$1.84M	Sell	478,810 -1,993	-0.4%	-$7.16K	﹤0.01%	2982
2023 Q2	$1.58M	Buy	480,803 +372,151	+343%	+$1.26M	﹤0.01%	3147
2023 Q1	$280K	Buy	108,652 +11,328	+12%	+$26.8K	﹤0.01%	3705
2022 Q4	$181K	Sell	97,324 -10	-0%	-$17	﹤0.01%	3909
2022 Q3	$179K	Buy	97,334 +14,121	+17%	+$29.5K	﹤0.01%	3923
2022 Q2	$179K	Sell	83,213 -468	-0.6%	-$1.13K	﹤0.01%	3977
2022 Q1	$263K	Sell	83,681 -3,546	-4%	-$11.2K	﹤0.01%	4015
2021 Q4	$280K	Hold	87,227	–	–	﹤0.01%	4053
2021 Q3	$293K	Buy	87,227 +5,175	+6%	+$18.9K	﹤0.01%	3994
2021 Q2	$321K	Sell	82,052 -399,811	-83%	-$1.58M	﹤0.01%	3902
2021 Q1	$1.94M	Sell	481,863 -19,386	-4%	-$64.4K	﹤0.01%	3260
2020 Q4	$1.16M	Buy	501,249 +16,990	+4%	+$79.2K	﹤0.01%	3463
2020 Q3	$2.78M	Sell	484,259 -21,228	-4%	-$142K	﹤0.01%	2885
2020 Q2	$3.73M	Buy	505,487 +435,638	+624%	+$2.04M	﹤0.01%	2693
2020 Q1	$209K	Buy	69,849 +19,028	+37%	+$64.1K	﹤0.01%	3674
2019 Q4	$211K	Sell	50,821 -7,895	-13%	-$24.9K	﹤0.01%	3772
2019 Q3	$190K	Sell	58,716 -121,775	-67%	-$277K	﹤0.01%	3776
2019 Q2	$334K	Sell	180,491 -8,861	-5%	-$15.8K	﹤0.01%	3666
2019 Q1	$336K	Buy	189,352 +50,481	+36%	+$126K	﹤0.01%	3641
2018 Q4	$336K	Sell	138,871 -2,862	-2%	-$13.1K	﹤0.01%	3645
2018 Q3	$804K	Buy	141,733 +12,236	+9%	+$92.8K	﹤0.01%	3526
2018 Q2	$1.01M	Buy	129,497 +11,067	+9%	+$95K	﹤0.01%	3450
2018 Q1	$837K	Buy	118,430 +53,264	+82%	+$431K	﹤0.01%	3434
2017 Q4	$643K	Buy	65,166 +7,619	+13%	+$70K	﹤0.01%	3502
2017 Q3	$493K	Hold	57,547	–	–	﹤0.01%	3575
2017 Q2	$604K	Buy	+57,547	New	+$751K	﹤0.01%	3547

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Northern Trust's OVID Position: Q1 2026 in Review

Northern Trust increased its Ovid Therapeutics (OVID) stake by 53% in Q1 2026, buying an estimated $158K and bringing the position to 254,804 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #3569.

Northern Trust first reported a position in OVID in Q2 2017 and has held it in 36 quarters since. The position peaked at $3.73M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Northern Trust held 254,804 shares of Ovid Therapeutics worth $566K as of Q1 2026.
Northern Trust bought 88,173 Ovid Therapeutics shares in Q1 2026, an estimated $158K.
Ovid Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3569 holding.
Northern Trust first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 36 quarters since.
Northern Trust's Ovid Therapeutics position peaked at $3.73M in Q2 2020.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.